Zimmer Biomet Investing in Musculoskeletal Diagnostics

The ortho giant has acquired CD Diagnostics for an undisclosed sum.

Chris Newmarker

Zimmer Biomet announced this week that it has bought CD Diagnostics (Claymont, DE), which has a specialty in developing immunoassays and biomarker testing.

In 2012, CD Diagnostics worked with Zimmer Biomet on musculoskeletal healthcare diagnostics, including the Synovasure periprosthetic joint infection (PJI) test.

"Our acquisition of CD Diagnostics cements our leadership and competitive advantage in musculoskeletal diagnostics, strengthens our Signature Solutions offering, and advances our mission to provide comprehensive musculoskeletal healthcare," Dan Williamson, Zimmer Biomet's group president for joint reconstruction, said in a news release.

"As value-based healthcare replaces fee-for-service models, there will be a growing need for diagnostics that can either prevent or minimize costly complications, or personalize the course of treatment to speed up recovery time and optimize the patient experience and, ultimately, the patient's outcome," Williamson said.

Financial terms of the deal were not disclosed.

The news comes about two months after Zimmer Biomet announced its plans to pruchase spinal device company LDR Holding Corp. for $1 billion.

(Find out how process innovations in 3-D printing are enabling next-generation medical devices at the MD&M Minneapolis conference on September 22. Qmed readers get 20% off with promo code Qmed16.)

Chris Newmarker is senior editor of Qmed. Follow him on Twitter at @newmarker.

Like what you're reading? Subscribe to our daily e-newsletter.